Patricia Reant

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial.

Journal: JAMA cardiology

Published: June 17, 2026

Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis.

Sex Differences in Phenotype and Tafamidis-Associated Survival in Val122Ile Transthyretin Cardiac Amyloidosis.

Journal: JACC. Heart failure

Published: March 03, 2026

Sudden cardiac death and major arrhythmic events in patients with Fabry disease: risk stratification in the FHFc multicenter study.

Sudden cardiac death and major arrhythmic events in patients with Fabry disease: risk stratification in the FHFc multicenter study.

Journal: Heart rhythm

Published: January 09, 2026

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of the American College of Cardiology

Published: October 11, 2025

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.

Journal: Journal of the American College of Cardiology

Published: October 11, 2025

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.

Journal: The New England journal of medicine

Published: September 01, 2025

Phenotype, genotype and prognosis of apical hypertrophic cardiomyopathies: a French multicentric cohort.

Phenotype, genotype and prognosis of apical hypertrophic cardiomyopathies: a French multicentric cohort.

Journal: European heart journal. Cardiovascular Imaging

Published: August 20, 2025

Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old.

Characteristics and Prognosis of Wild-Type Transthyretin Amyloid Cardiomyopathy Patients Diagnosed Before 65 Years Old.

Journal: JACC. Advances

Published: August 07, 2025

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.

Journal: Journal of the American College of Cardiology

Published: July 24, 2025

Laminopathies: natural history and risk prediction of heart failure.

Laminopathies: natural history and risk prediction of heart failure.

Journal: European heart journal

Published: June 06, 2025

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.

Journal: Archives of cardiovascular diseases

Published: June 02, 2025

Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry.

Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry.

Journal: International journal of cardiology

Published: April 17, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026